- Home
- MBAV vs TNGX Comparison
MBAV vs TNGX Comparison
Compare MBAV & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBAV
- TNGX
- Stock Information
- Founded
- MBAV 2024
- TNGX 2014
- Country
- MBAV United States
- TNGX United States
- Employees
- MBAV N/A
- TNGX N/A
- Industry
- MBAV
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MBAV
- TNGX Health Care
- Exchange
- MBAV NYSE
- TNGX Nasdaq
- Market Cap
- MBAV 388.5M
- TNGX 723.0M
- IPO Year
- MBAV 2024
- TNGX N/A
- Fundamental
- Price
- MBAV $10.60
- TNGX $6.04
- Analyst Decision
- MBAV
- TNGX Strong Buy
- Analyst Count
- MBAV 0
- TNGX 5
- Target Price
- MBAV N/A
- TNGX $10.50
- AVG Volume (30 Days)
- MBAV 590.8K
- TNGX 1.6M
- Earning Date
- MBAV 01-01-0001
- TNGX 08-05-2025
- Dividend Yield
- MBAV N/A
- TNGX N/A
- EPS Growth
- MBAV N/A
- TNGX N/A
- EPS
- MBAV 0.28
- TNGX N/A
- Revenue
- MBAV N/A
- TNGX $40,990,000.00
- Revenue This Year
- MBAV N/A
- TNGX N/A
- Revenue Next Year
- MBAV N/A
- TNGX N/A
- P/E Ratio
- MBAV $38.24
- TNGX N/A
- Revenue Growth
- MBAV N/A
- TNGX 10.09
- 52 Week Low
- MBAV $9.97
- TNGX $1.03
- 52 Week High
- MBAV $13.73
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- MBAV N/A
- TNGX 52.37
- Support Level
- MBAV N/A
- TNGX $6.36
- Resistance Level
- MBAV N/A
- TNGX $7.11
- Average True Range (ATR)
- MBAV 0.00
- TNGX 0.48
- MACD
- MBAV 0.00
- TNGX -0.15
- Stochastic Oscillator
- MBAV 0.00
- TNGX 17.14
About MBAV M3-BRIGADE ACQUISITION V CORP
M3-Brigade Acquisition V Corp is a blank check company.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.